Cambridge Investment Research Advisors’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.03M | Sell |
45,009
-5,285
| -11% | -$352K | 0.01% | 1376 |
|
|
2026
Q1 | $3.16M | Buy |
50,294
+11,835
| +31% | +$824K | 0.01% | 1253 |
|
|
2025
Q4 | $2.55M | Buy |
38,459
+25,381
| +194% | +$1.64M | 0.01% | 1334 |
|
|
2025
Q3 | $880K | Sell |
13,078
-24,088
| -65% | -$1.91M | ﹤0.01% | 2147 |
|
|
2025
Q2 | $3.24M | Buy |
37,166
+14,459
| +64% | +$1.13M | 0.01% | 1106 |
|
|
2025
Q1 | $1.55M | Sell |
22,707
-1,691
| -7% | -$138K | 0.01% | 1523 |
|
|
2024
Q4 | $1.9M | Sell |
24,398
-1,460
| -6% | -$108K | 0.01% | 1393 |
|
|
2024
Q3 | $1.73M | Sell |
25,858
-3,788
| -13% | -$311K | 0.01% | 1464 |
|
|
2024
Q2 | $3.36M | Sell |
29,646
-21,619
| -42% | -$2.73M | 0.01% | 969 |
|
|
2024
Q1 | $7.11M | Sell |
51,265
-16,667
| -25% | -$2.1M | 0.03% | 585 |
|
|
2023
Q4 | $8.43M | Buy |
67,932
+41,469
| +157% | +$4.24M | 0.04% | 470 |
|
|
2023
Q3 | $2.47M | Buy |
26,463
+5,222
| +25% | +$589K | 0.01% | 999 |
|
|
2023
Q2 | $2.73M | Sell |
21,241
-13,221
| -38% | -$1.6M | 0.01% | 988 |
|
|
2023
Q1 | $4M | Buy |
34,462
+9,182
| +36% | +$1.03M | 0.02% | 746 |
|
|
2022
Q4 | $2.86M | Buy |
25,280
+3,656
| +17% | +$401K | 0.01% | 888 |
|
|
2022
Q3 | $1.74M | Buy |
21,624
+1,082
| +5% | +$91.6K | 0.01% | 1109 |
|
|
2022
Q2 | $1.53M | Sell |
20,542
-3,162
| -13% | -$289K | 0.01% | 1190 |
|
|
2022
Q1 | $3.03M | Sell |
23,704
-5,756
| -20% | -$630K | 0.01% | 904 |
|
|
2021
Q4 | $3.96M | Sell |
29,460
-4,716
| -14% | -$678K | 0.02% | 765 |
|
|
2021
Q3 | $4.67M | Buy |
34,176
+5,460
| +19% | +$689K | 0.02% | 642 |
|
|
2021
Q2 | $3.06M | Sell |
28,716
-2,252
| -7% | -$216K | 0.01% | 883 |
|
|
2021
Q1 | $2.78M | Buy |
30,968
+8,400
| +37% | +$789K | 0.02% | 838 |
|
|
2020
Q4 | $2.09M | Buy |
22,568
+1,692
| +8% | +$151K | 0.01% | 903 |
|
|
2020
Q3 | $2.15M | Sell |
20,876
-6,528
| -24% | -$682K | 0.01% | 766 |
|
|
2020
Q2 | $2.78M | Buy |
27,404
+9,744
| +55% | +$872K | 0.02% | 639 |
|
|
2020
Q1 | $1.19M | Buy |
17,660
+3,448
| +24% | +$215K | 0.01% | 891 |
|
|
2019
Q4 | $777K | Sell |
14,212
-3,460
| -20% | -$164K | 0.01% | 1298 |
|
|
2019
Q3 | $659K | Sell |
17,672
-632
| -3% | -$24.6K | 0.01% | 1320 |
|
|
2019
Q2 | $686K | Sell |
18,304
-8,284
| -31% | -$260K | 0.01% | 1244 |
|
|
2019
Q1 | $792K | Buy |
26,588
+11,100
| +72% | +$390K | 0.01% | 1172 |
|
|
2018
Q4 | $464K | Sell |
15,488
-1,348
| -8% | -$42.8K | 0.01% | 1367 |
|
|
2018
Q3 | $602K | Buy |
+16,836
| New | +$522K | 0.01% | 1336 |
|
Other funds holding DXCM
Cambridge Investment Research Advisors's DXCM Position: Q2 2026 in Review
Cambridge Investment Research Advisors reduced its DexCom (DXCM) stake by 11% in Q2 2026, selling an estimated $352K and leaving 45,009 shares worth $3.03M. The position accounts for 0.01% of the portfolio, ranked #1376.
Cambridge Investment Research Advisors first reported a position in DXCM in Q3 2018 and has held it in 32 quarters since. The position peaked at $8.43M in Q4 2023. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.
- Cambridge Investment Research Advisors held 45,009 shares of DexCom worth $3.03M as of Q2 2026.
- Cambridge Investment Research Advisors sold 5,285 DexCom shares in Q2 2026, an estimated $352K.
- DexCom made up 0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1376 holding.
- Cambridge Investment Research Advisors first reported a position in DexCom in Q3 2018 and has held it in 32 quarters since.
- Cambridge Investment Research Advisors's DexCom position peaked at $8.43M in Q4 2023.
- 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.
Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.